文献速递多重用药衰弱、肌少症与跌倒老年慢病共病管理

潜在不适当用药对老年人失能与死亡的影响:韩国全国性人群研究

Impact of Potentially Inappropriate Medication on Disability and Mortality in Older Adults: Nationwide Population-Based Study in Korea.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

结果显示PIM组失能、全因死亡及复合终点风险均显著高于非PIM组,且风险随PIM数量增加而升高,调整衰弱与多重用药后关联仍存在。

要点

  • PIM组失能风险HR 1.22,死亡风险HR 1.15,复合终点HR 1.16。
  • PIM数量越多,失能、死亡及复合终点风险显著增加。
  • 调整衰弱与多重用药后,PIM与不良结局的关联仍存在。

核心结论

  • 老年人使用PIM与失能和死亡风险升高相关,且风险随PIM数量增加而增大。
  • 调整衰弱与多重用药后,PIM与不良结局的关联仍然存在。

研究设计与样本

  • 基于韩国国民健康保险服务与国家过渡年龄筛查项目(NSPTA)的全国性人群研究。

主要发现

  • PIM组(64.4%)失能发生率为2.3%,非PIM组为1.2%(p < .001)。
  • PIM组死亡发生率为3.6%,非PIM组为2.4%(p < .001)。
  • PIM组复合终点发生率为5.3%,非PIM组为3.2%(p < .001)。
  • PIM使用与失能(HR 1.22 [95% CI, 1.16, 1.28])、死亡(HR 1.15 [95% CI 1.11, 1.19])及复合终点(HR 1.16 [95% CI, 1.13, 1.20])风险升高相关,调整衰弱与多重用药后仍显著。

关键数值与推荐

  • PIM数量分组为0、1-2、3-4、≥5时,失能、死亡及复合终点风险均显著增加(all p < .001)。

临床怎么用

  • 对老年患者应评估PIM使用情况,尤其关注PIM数量较多者,以降低失能与死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potentially inappropriate medications (PIMs) increase the risk of adverse health outcomes in older adults. However, the long-term effects of PIMs, particularly considering frailty and polypharmacy, remain unclear. METHODS: We analyzed data from the National Health Insurance Service and the National Screening Program for Transitional Ages (NSPTA) in Korea, including individuals aged 66 who participated between 2015 and 2016. Participants were categorized into PIM and No PIM groups based on prescriptions, with frailty index calculated from NSPTA results. Outcomes were tracked over 6.77 years. The primary outcome was disability; secondary outcomes included all-cause mortality and a composite endpoint of death or disability. The association between PIM and adverse outcomes was evaluated using Cox proportional hazard models. RESULTS: A total of 564 036 individuals were included. During follow-up, 10 735 (1.9%) developed disabilities, and 17 887 (3.1%) died. The PIM group (64.4%) showed higher risks of disability (2.3% vs 1.2%) and mortality (3.6% vs 2.4%) compared with the No PIM group (p < .001). The composite outcome was also more frequent in the PIM group (5.3%) compared with the No PIM group (3.2%; p < .001). PIM use was associated with increased risks of disability (HR 1.22 [95% CI, 1.16, 1.28]), mortality (HR 1.15 [95% CI 1.11, 1.19]), and the composite outcome (HR 1.16 [95% CI, 1.13, 1.20]), even after adjusting for frailty and polypharmacy. Furthermore, as the number of PIMs increased (0, 1-2, 3-4, ≥5), the risks of disability, mortality, and the composite outcome also significantly increased (all p < .001). CONCLUSION: PIM use in older adults raises the risk of disability and mortality, even after adjusting to frailty and polypharmacy, and the impact grows with the number of PIMs prescribed.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Jung HW, Park SJ, Jhang H, et al. Impact of Potentially Inappropriate Medication on Disability and Mortality in Older Adults: Nationwide Population-Based Study in Korea. J Gerontol A Biol Sci Med Sci. 2025. PMID: 40037568. doi:10.1093/gerona/glaf045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。